Datroway® (datopotamab deruxtecan-dlnk)
for Breast Cancer

Datroway (datopotamab deruxtecan) is an antibody-drug conjugate (ADC) used to treat metastatic HR-positive, HER2-negative breast cancer. It is prescribed for patients whose cancer is unresectable or has spread and who have received prior treatments. Datroway targets Trop-2, delivering chemotherapy directly into cancer cells to slow tumor growth and shrink cancer.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Breast Cancer